广告品牌策划模板

Recently, the cooperative research paper "Enhanced Antitumor Immunity of a Globo H-Based Vaccine Enabled by the Combination Adjustments of 3D-MPL and QS-21", developed by Chengdu Maikekang Biotechn...

On July 13th, the Phase III clinical trial of the recombinant herpes zoster vaccine (CHO cells) of Chengdu MAXVAX Biotechnology Co., Ltd. (referred to as "MAXVAX Biotechnology") completed with the ...

The key to international cooperation in technological innovation is to establish communication and connections, and the best way to achieve this is through people with good relationships international

On June 28, 2024, Chengdu MAXVAX Biotechnology Co., Ltd. announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration has approved its application for clinica...

In June 2024, Chengdu MAXVAX Biotechnology Co., Ltd. (hereinafter referred to as "MAXVAX Biotechnology") announced that it had received over 300 million yuan in Series C financing. This round of...

On the morning of May 19th, representatives from Chongqing Modern Industry Research Institute conducted research on the Shanghai Innovation Vaccine Transfer Platform of Maikekang Biotechnology. Mr. Zo

On May 6th, the kickoff meeting for the Phase II clinical trial of the recombinant herpes zoster vaccine (CHO cells) by Chengdu Maikekang Biotechnology Co., Ltd. (referred to as "Maikekang Biotechnolo

On the morning of April 20th, Yuan Quan, Deputy Secretary of the Fengxian District Committee and District Mayor of Shanghai, led a team to investigate the "Innovative Vaccine Transfer Platform" projec

On April 12, 2024, Chengdu Maxvax Biotechnology Co., Ltd. (referred to as "Maxvax Biotechnology") announced that its independently developed and jointly applied by its wholly-owned subsidiary fo

On December 29, 2023, the BRD Shanghai Biomedical Innovation and Development Conference arrived as scheduled, with a gathering of experts on site. The preparatory party for this conference, Pharmaceut